Keyphrases
Belatacept
100%
Cyclosporine
100%
Extended Criteria Donor
100%
Long-term Exposure
100%
Donor Kidney
100%
Long-term Extension
50%
Continuation Treatment
25%
Post-transplant Lymphoproliferative Disorder
25%
Graft Loss
12%
Transplantation
12%
Safety Profile
12%
Long-term Extension Study
12%
Viral Infection
12%
Fungal Infection
12%
Immunosuppression Regimen
12%
Incidence Rate
12%
Epstein-Barr Virus
12%
Infection Infection
12%
Serious Adverse Events
12%
Sustained Improvement
12%
Renal Function Improvement
12%
Profile Modification
12%
Acute Rejection Episode
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ciclosporin
100%
Long Term Exposure
100%
Belatacept
100%
Posttransplant Lymphoproliferative Disease
25%
Epstein-Barr Virus
12%
Virus Infection
12%
Adverse Event
12%
Acute Graft Rejection
12%
Graft Failure
12%
Mycosis
12%
Immunology and Microbiology
Ciclosporin
100%
Belatacept
100%
Lymphoproliferative Disorders
25%
Immunosuppression
12%
Viral Disease
12%
Acute Graft Rejection
12%
Kidney Function
12%
Epstein Barr Virus
12%